Literature DB >> 20209495

Metastasis suppressor function of NM23-H1 requires its 3'-5' exonuclease activity.

Qingbei Zhang1, Joseph R McCorkle, Marian Novak, Mengmeng Yang, David M Kaetzel.   

Abstract

The metastasis suppressor NM23-H1 possesses 3 enzymatic activities in vitro, a nucleoside diphosphate kinase (NDPK), a protein histidine kinase and a more recently characterized 3'-5' exonuclease. Although the histidine kinase has been implicated in suppression of motility in breast carcinoma cell lines, potential relevance of the NDPK and 3'-5' exonuclease to metastasis suppressor function has not been addressed in detail. To this end, site-directed mutagenesis and biochemical analyses of bacterially expressed mutant NM23-H1 proteins have identified mutations that disrupt the 3'-5' exonuclease alone (Glu(5) to Ala, or E(5) A), the NDPK and histidine kinase activities tandemly (Y(52) A, H(118) F) or all 3 activities simultaneously (K(12) Q). Although forced expression of NM23-H1 potently suppressed spontaneous lung metastasis of subcutaneous tumor explants derived from the human melanoma cell line 1205LU, no significant metastasis suppressor activity was obtained with the exonuclease-deficient variants E(5) A and K(12) Q. The H(118) F mutant, which lacked both the NDPK and histidine kinase while retaining the 3'-5' exonuclease, also exhibited compromised suppressor activity. In contrast, each mutant retained the ability to suppress motility and invasive characteristics of 1205LU cells in culture, indicating that the NM23-H1 molecule possesses an additional activity(s) mediating these suppressor functions. These studies provide the first demonstration that the 3'-5' exonuclease activity of NM23-H1 is necessary for metastasis suppressor function and further indicate cooperativity of the 3 enzymatic activities of the molecule on suppression of the metastatic process.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20209495      PMCID: PMC2946830          DOI: 10.1002/ijc.25307

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

1.  NM23-H1 and NM23-H2 repress transcriptional activities of nuclease-hypersensitive elements in the platelet-derived growth factor-A promoter.

Authors:  Deqin Ma; Zhenlan Xing; Bin Liu; Nancy G Pedigo; Stephen G Zimmer; Zengliang Bai; Edith H Postel; David M Kaetzel
Journal:  J Biol Chem       Date:  2001-11-01       Impact factor: 5.157

2.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

3.  Evidence for a novel gene associated with low tumor metastatic potential.

Authors:  P S Steeg; G Bevilacqua; L Kopper; U P Thorgeirsson; J E Talmadge; L A Liotta; M E Sobel
Journal:  J Natl Cancer Inst       Date:  1988-04-06       Impact factor: 13.506

4.  Development of invasive and growth factor-independent cell variants from primary human melanomas.

Authors:  R Kath; J A Jambrosic; L Holland; U Rodeck; M Herlyn
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

5.  Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development.

Authors:  A M Rosengard; H C Krutzsch; A Shearn; J R Biggs; E Barker; I M Margulies; C R King; L A Liotta; P S Steeg
Journal:  Nature       Date:  1989-11-09       Impact factor: 49.962

6.  In vitro properties of human melanoma cells metastatic in nude mice.

Authors:  D Herlyn; D Iliopoulos; P J Jensen; A Parmiter; J Baird; H Hotta; K Adachi; A H Ross; J Jambrosic; H Koprowski
Journal:  Cancer Res       Date:  1990-04-15       Impact factor: 12.701

Review 7.  Nm23/nucleoside diphosphate kinase in human cancers.

Authors:  M T Hartsough; P S Steeg
Journal:  J Bioenerg Biomembr       Date:  2000-06       Impact factor: 2.945

8.  Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity.

Authors:  A Leone; U Flatow; K VanHoutte; P S Steeg
Journal:  Oncogene       Date:  1993-09       Impact factor: 9.867

9.  Nucleoside diphosphate kinase/NM23 expression in breast cancer: lack of correlation with lymph-node metastasis.

Authors:  X Sastre-Garau; M L Lacombe; M Jouve; M Véron; H Magdelénat
Journal:  Int J Cancer       Date:  1992-02-20       Impact factor: 7.396

10.  Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme.

Authors:  A M Gilles; E Presecan; A Vonica; I Lascu
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

View more
  40 in total

1.  Nm23-H1 regulates glucose-stimulated insulin secretion in pancreatic β-cells via Arf6-Rac1 signaling axis.

Authors:  Rajakrishnan Veluthakal; David Kaetzel; Anjaneyulu Kowluru
Journal:  Cell Physiol Biochem       Date:  2013-08-30

Review 2.  Protein-protein interactions: a mechanism regulating the anti-metastatic properties of Nm23-H1.

Authors:  Natascia Marino; Jean-Claude Marshall; Patricia S Steeg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-06-29       Impact factor: 3.000

3.  A critical evaluation of biochemical activities reported for the nucleoside diphosphate kinase/Nm23/Awd family proteins: opportunities and missteps in understanding their biological functions.

Authors:  Patricia S Steeg; Massimo Zollo; Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-25       Impact factor: 3.000

4.  Progress on Nme (NDP kinase/Nm23/Awd) gene family-related functions derived from animal model systems: studies on development, cardiovascular disease, and cancer metastasis exemplified.

Authors:  Tien Hsu; Patricia S Steeg; Massimo Zollo; Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-15       Impact factor: 3.000

Review 5.  Nucleoside diphosphate kinases (NDPKs) in animal development.

Authors:  Krisztina Takács-Vellai; Tibor Vellai; Zsolt Farkas; Anil Mehta
Journal:  Cell Mol Life Sci       Date:  2014-12-24       Impact factor: 9.261

6.  Dual functions of NME1 in suppression of cell motility and enhancement of genomic stability in melanoma.

Authors:  David M Kaetzel; Mary K Leonard; Gemma S Cook; Marian Novak; Stuart G Jarrett; Xiuwei Yang; Alexey M Belkin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-07-15       Impact factor: 3.000

7.  The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma.

Authors:  Joseph R McCorkle; Mary K Leonard; Susan D Kraner; Eric M Blalock; Deqin Ma; Stephen G Zimmer; David M Kaetzel
Journal:  Cancer Genomics Proteomics       Date:  2014 Jul-Aug       Impact factor: 4.069

Review 8.  Multiple mechanisms underlie metastasis suppressor function of NM23-H1 in melanoma.

Authors:  Marian Novak; Stuart G Jarrett; Joseph R McCorkle; Isabel Mellon; David M Kaetzel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-03-30       Impact factor: 3.000

9.  NME1 Drives Expansion of Melanoma Cells with Enhanced Tumor Growth and Metastatic Properties.

Authors:  Ying Wang; M Kathryn Leonard; Devin E Snyder; Matthew L Fisher; Richard L Eckert; David M Kaetzel
Journal:  Mol Cancer Res       Date:  2019-05-23       Impact factor: 5.852

10.  A splicing variant of NME1 negatively regulates NF-κB signaling and inhibits cancer metastasis by interacting with IKKβ.

Authors:  Dong-Joo You; Cho Rong Park; Hyun Bok Lee; Mi Jin Moon; Ju-Hee Kang; Cheolju Lee; Seong-Hyun Oh; Curie Ahn; Jae Young Seong; Jong-Ik Hwang
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.